Scope Ophthalmics has partnered with TearLab to commercialise what was claimed to be the first objective and quantitative diagnostic device for dry eye disease.
The TearLab Osmolarity System allowed clinicians to measure the osmolarity of human tears, helping to diagnose and manage patients suspected of having dry eye disease.
Following the partnership, Scope was adding a team of four to its existing sales team, including three TearLab specialists and business unit manager.
Scope Ophthalmics director Tom Freyne said: ‘We are delighted to partner with Tearlab in the UK and Ireland. By adding a diagnostics dimension to the existing strong portfolio of dry eye disease and blepharitis products it ensures that the patient is receiving the right treatment for their condition.’
Arthur Cummings, consultant eye surgeon at the Wellington Eye Clinic, said: ‘Taking care of dry eye prior to cataract and refractive surgery provides better patient outcomes. TearLab can also be used to manage and monitor dry eye disease following cataract and refractive surgery and thereby facilitate the best possible post-operative care.’
